Janux Therapeutics Inc [JANX] stock is trading at $14.81, down -2.18%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The JANX shares have gain 7.94% over the last week, with a monthly amount glided 5.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Barclays started tracking the stock with Overweight rating on September 17, 2025, and set its price target to $47. On September 10, 2025, Truist initiated with a Buy rating and assigned a price target of $100 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $45 on September 10, 2025. Guggenheim initiated its recommendation with a Buy and recommended $72 as its price target on September 04, 2025. Piper Sandler started tracking with a Overweight rating for this stock on August 19, 2025, and assigned it a price target of $42. In a note dated July 11, 2025, Raymond James initiated an Outperform rating and provided a target price of $65 on this stock.
Janux Therapeutics Inc [JANX] stock has fluctuated between $12.80 and $47.58 over the past year. Currently, Wall Street analysts expect the stock to reach $45.17 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $14.81 at the most recent close of the market. An investor can expect a potential return of 205.0% based on the average JANX price forecast.
Analyzing the JANX fundamentals
Janux Therapeutics Inc [NASDAQ:JANX] reported sales of 10.00M for the trailing twelve months, which represents a growth of 2177.90%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -14.43%, Pretax Profit Margin comes in at -10.19%, and Net Profit Margin reading is -10.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.1 and Total Capital is -0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Janux Therapeutics Inc’s Current Ratio is 35.86. Further, the Quick Ratio stands at 35.86, while the Cash Ratio is 1.74. Considering the valuation of this stock, the price to sales ratio is 89.08, the price to book ratio is 0.91.
Transactions by insiders
Recent insider trading involved ANDY MEYER, Former Affiliate, that happened on Jan 23 ’26 when 0.12 million shares were purchased. Chief Business Officer, Meyer Andrew Hollman completed a deal on Jan 02 ’26 to sell 1879.0 shares. Meanwhile, Chief Scientific Officer DiRaimondo Thomas sold 2505.0 shares on Jan 02 ’26.
